Arrowhead Research Reports $428 Million Quarterly Loss

The Pasadena drug developer's fiscal fourth-quarter loss and revenue both fell short of analyst estimates.

Updated on Nov. 12, 2026 in Corporate Finance

Clear, sober laboratory bench with plain glass flasks and a steel pipette stand, a window behind it framing dry foothills under a clear sky.
Arrowhead Research Corp. reported a $428 million fiscal fourth-quarter loss on Thursday, November 12, 2026, with revenue of $37.8 million falling short of analyst estimates. AI Illustration. Upload story photo >

Arrowhead Research Corp. reported a fiscal fourth-quarter loss of $428 million, or $3.04 per share, and revenue of $37.8 million. Both figures came in below the average analyst estimates of a $1.59 loss per share and $66.3 million in revenue.

Why it matters

The results show a sharper quarterly shortfall than analysts expected for the drug developer. Investors are weighing these losses against a share price that has fallen 29% since the start of the year.

Full-year net loss totaled $724.2 million, or $5.11 per share, on revenue of $450.8 million. The source does not indicate what drove the gap between reported results and analyst expectations.

The players

Arrowhead Research Corp.

A drug developer based in Pasadena, California, whose quarterly results missed analyst expectations.

The details

Arrowhead Research Corp., a drug developer based in Pasadena, California, reported its fiscal fourth-quarter results on Thursday, November 12, 2026. Shares closed near $47.15 in the final minutes of trading that day, and have risen 14% over the last 12 months.

Timeline

  1. Thursday, November 12, 2026: Fiscal fourth-quarter results reported; shares close near $47.15.

  2. Beginning of 2026: Shares begin a 29% decline that continues through the reporting date.

Market Landscape

Arrowhead's results were measured against Zacks Investment Research analyst averages, which set the benchmark for the quarter's $1.59 loss-per-share and $66.3 million revenue expectations. The company's 14% gain over the last 12 months contrasts with its 29% decline since the start of the year.

Shareholders who bought shares 12 months ago are up 14%, while those who bought at the start of the year are down 29%. The results may affect how investors weigh the company's position in their portfolios.

The takeaway

Quarterly results that miss analyst consensus can shift how investors value a company even when its longer-term share price trend is positive. Comparing reported figures to the expectations they were measured against gives clearer context than the headline loss alone.

Further reading

Track more quarterly results and company earnings in Corporate Finance.

Source note: This article includes information reported by WTOP.